Kronos Bio Inc. (KRON): Price and Financial Metrics
KRON Price/Volume Stats
| Current price | $0.96 | 52-week high | $2.29 |
| Prev. close | $1.01 | 52-week low | $0.73 |
| Day low | $0.93 | Volume | 173,000 |
| Day high | $1.02 | Avg. volume | 243,349 |
| 50-day MA | $1.15 | Dividend yield | N/A |
| 200-day MA | $1.27 | Market Cap | 57.69M |
KRON Stock Price Chart Interactive Chart >
Kronos Bio Inc. (KRON) Company Bio
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Latest KRON News From Around the Web
Below are the latest news stories about KRONOS BIO INC that investors may wish to consider to help them evaluate KRON as an investment opportunity.
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidatePhase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New development candidate KB-9558 inhibits the KAT domain of p300 and thereby modulates IRF4, a key driver of multiple myeloma; IND-enabling studies underway for expected completion in Q4 2024 Kronos Bio’s first development candidate, KB-0742, cleared 80 mg dose in dose escalation portion of the phase 1/2 trial; |
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceSAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December |
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare ConferenceSAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN Mapping will participate in a fireside chat at the 35th Annual Piper S |
Kronos Bio Up 47%, Insider Buyers Are Up 31%Kronos Bio, Inc. ( NASDAQ:KRON ) insiders who purchased shares in the last 12 months were richly rewarded last week... |
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue EstimatesKronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
KRON Price Returns
| 1-mo | -24.41% |
| 3-mo | -18.64% |
| 6-mo | 9.09% |
| 1-year | -26.15% |
| 3-year | -95.86% |
| 5-year | N/A |
| YTD | -23.20% |
| 2023 | -22.84% |
| 2022 | -88.08% |
| 2021 | -54.50% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...